Building a medtech brand?
We run PR and public affairs for companies in this market: from category launches and funding announcements to NHS procurement and regulatory communications.
Optellum
Lung cancer diagnosis AI
Diagnostics & imaging
AI decision-support software that stratifies the cancer risk of lung nodules found on CT scans, the first such tool cleared by the FDA.
The read
Optellum's Virtual Nodule Clinic analyses CT scans to estimate the malignancy risk of incidentally found lung nodules, helping clinicians decide between immediate biopsy, active surveillance or discharge. It was the first AI-powered clinical decision support software cleared by the FDA for early lung cancer diagnosis, in March 2021.
In January 2026 it was selected for an NHS end-to-end lung cancer diagnostic pathway alongside Intuitive Surgical's robotic bronchoscopy, led by Guy's and St Thomas'. A March 2026 Vanderbilt-led study found its AI cost-effective from a US payer perspective, a harder commercial bar than regulatory clearance alone.
The Bridgehead view
Optellum's move from pilot evaluations to reimbursement-grade evidence and a named NHS end-to-end pathway shows the diagnostics-AI category maturing past the clearance-as-endpoint phase into the harder work of proving payer economics.
Work with us
Working across the healthcare sector?
We advise NHS-facing organisations, providers and health systems on reputation, policy engagement and communications that understand the sector.
Related platforms
Others in the sector map
Stroke and lung imaging AI
Brainomix
Oxford University spinout building AI imaging biomarkers for stroke and lung disease, used to speed emergency treatment decisions from CT and MRI scans.
ReadDermatology AI
Skin Analytics
AI-powered skin cancer detection device, DERM, deployed directly within NHS urgent skin cancer pathways to autonomously rule out low-risk cases.
ReadThe firm that knows medtech
We map this sector because
we represent it.
Whether you build medical technology or run the health systems that buy it, we know the market, the media and the regulatory landscape it operates in. Thirty minutes with a partner tells you if we can help.
